Business
Camp4 is a clinical-stage biopharma company developing RNA-based therapeutics intended to raise gene expression and restore healthy protein levels in genetic disease.
Camp4 grew collaboration revenue to $3.5M and cut cash burn, but the FY2025 loss widened to $80.4M as CMP-002 stayed preclinical.
The read at a glance✓ Audited against SEC data
- Business mix — RNA medicinesNote
- Revenue — $3.5M, +436.5%OK
- Net income — -$80.4M, worseWatch
- FCF — -$29.8M, improvedOK
- Insiders — $4.8M purchases / 0 salesOK
- Balance — Equity $47.7M, -24.5%Watch
- Accounting — Altman distressWatch
Where the revenue comes from
Fiscal 2025, as Camp4 Therapeutics Corp reports it. History and quarterly detail are in the app.
- R&D$3.5M
Leadership changes
From Camp4 Therapeutics Corp's own filings, the day they're filed.
- Michael MacLean · director · appointmenteff. 2026-04-01
- Paula Ragan · directors · departureeff. 2025-09-09
- Douglas Williams · director · appointmenteff. 2025-03-17
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-07-27
- 8-K · Company announcement2026-06-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Camp4 Therapeutics Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.